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Abstract
Background: There is little confidence in the consistency of estimation of DNA concentrations
when samples move between laboratories. Evidence on this consistency is largely anecdotal.
Therefore there is a need first to measure this consistency among different laboratories and then
identify and implement remedies. A pilot experiment to test logistics and provide initial data on
consistency was therefore conceived.
Methods: DNA aliquots at nominal concentrations between 10 and 300 ng/μl were dispensed into
the wells of 96-well plates by one participant - the coordinating centre. Participants estimated the
concentration in each well and returned estimates to the coordinating centre.
Published: 13 October 2009
BMC Research Notes 2009, 2:208 doi:10.1186/1756-0500-2-208
Received: 20 July 2009
Accepted: 13 October 2009
This article is available from: http://www.biomedcentral.com/1756-0500/2/208
© 2009 Yuille et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Research Notes 2009, 2:208 http://www.biomedcentral.com/1756-0500/2/208
Page 2 of 8
(page number not for citation purposes)
Results: Considerable overall variability was observed among estimates. There were statistically
significant differences between participants' measurements and between fluorescence emission and
absorption spectroscopy.
Conclusion:  Anecdotal evidence of variability in DNA concentration estimation has been
substantiated. Reduction in variability between participants will require the identification of major
sources of variation, specification of effective remedies and their implementation.
Introduction
Few genotyping labs will receive DNA at a stated concen-
tration and not estimate the concentration again. This
occurs because there is little confidence in the consistency
of estimations between labs. The receiving lab may then
require more DNA for concentration estimation than is
needed for the assay itself. The process is likely to be
repeated each time the same sample is assayed. When
many thousands of samples are to be genotyped, they
must be aggregated from multiple biobanks and months
are spent standardising concentration and quality.
In the report on the Wellcome Trust Case Control Consor-
tium [1] attention was given to DNA sample quality as a
cause of data loss. The report's Table Four shows that one
in 21 samples genotyped (809 out of 17,000 DNA sam-
ples) were excluded from analysis owing to problems of
DNA quality or sample labelling (i.e. data quality). The
single most substantial cause of exclusion appeared to be
the failure of a DNA sample to attain a single nucleotide
polymorphism call rate of >97%. This failure may arise
from impurities in the sample, its lack of homogeneity or
from inconsistency and or inaccuracy in DNA concentra-
tion estimation. Thus, even in well-curated series, time,
effort and money may be wasted and an essentially non-
renewable resource is depleted.
Medical genomics research requires increasing attention
to consistent high quality production and management of
both the samples and associated data that are to be the
subject of experimental analysis. This attention is neces-
sary because of the need to share resources. Resource shar-
ing involves the aggregation of samples and data from
multiple biobanks and, along with improvements in phe-
notyping [2] is widely recognised as essential for the next
generation of genetic epidemiology investigations [3].
Public Population Project in Genomics (P3G) [4] is an
organisation of researchers dedicated to fostering collabo-
ration and, thus, resource-sharing, in the field of popula-
tion genomics. Sharing resources includes aggregation of
samples from numerous sources. P3G reasoned that a
good starting point to address concerns about sample
quality in general [5] was through a focus on DNA. The
first issue here is to provide data to support anecdotal evi-
dence that DNA concentration estimations by different
laboratories and biobanks are inconsistent. P3G approved
[6] a study proposal on this issue from the UK DNA Bank-
ing Network [7]. The study proposal planned an observa-
tional study undertaken by biobanks that are members of
P3G or members of the Biobanking and BioMolecular
Resources Infrastructure Preparatory Phase (BBMRI) [8] -
the pan-European biobanking [9].
The aim of the pilot study described here is to test the
logistics for a larger scale study and to provide some initial
data on consistency between biobanks. This study seeks to
discover to what extent different laboratories and
biobanks obtain different estimates of the concentration
of the same DNA solution. No constraint is placed on the
technology or instrument used. The results demonstrate
substantial variability between participants, instruments
and technologies.
An observational study among forensic laboratories of
DNA concentration estimation methods and results has
been described [10]. Its aims were broader than the study
described here, examining the effects of DNA concentra-
tion on downstream processes and DNA stability. As far as
DNA concentration estimation is concerned, the authors
focussed solely on whether a method was quantitative.
Methods
DNA preparation and aliquotting
A DNA solution in TE (10 mM Tris, 1 mM EDTA pH 7.5,
Invitrogen #T11493) was prepared from three human cell
lines at a nominal concentration of 400 ng/μl by the Euro-
pean Collection of Cell Cultures (Salisbury, UK), consist-
ent with appropriate ethical use. The solution was stored
(4°C) at the coordinating centre (CIGMR, Manchester).
Agarose gel electrophoresis followed by ethidium bro-
mide staining did not detect degradation. The solution
was mixed thoroughly in its tube using a Labinco L46 Vor-
texer for 2 mins at speed setting 10. Volumes were
removed manually from the tube into 50 ml tubes
(Greiner #227261), diluted with TE to give nominal con-
centrations of 10, 40, 20, 50, 100, 150, 75, 300 ng/μl
(nominal).
For each of the DNA dilutions, either volumes of 20 μl or
40 μl were dispensed into four columns of a 96-well poly-
propylene plates (ABgene # AB-1058) using a Tecan Free-BMC Research Notes 2009, 2:208 http://www.biomedcentral.com/1756-0500/2/208
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dom 200 liquid handler (Tecan, Switzerland). The plates
were shipped on dry ice to each participant (identified
here by a number). They were asked to measure DNA con-
centration in all wells; to use their standard operating pro-
cedures for DNA concentration estimation; to return data
within 28 days.
Instruments used were as follows: (1) NanoDrop ND-
1000; (2) Molecular Devices SpectraMaxPlus384; (3)
Thermo Fluoroskan Ascent FL; (4) Tecan GENios; (5)
Pharmacia Photometer GeneQuant RNA/DNA Calcula-
tor; (6) BMG Labtech FLUOstar Galaxy; (7) Molecular
Devices SpectraMax Gemini XPS; (8) Eppendorf Biopho-
tometer. These instruments relied on one of two technol-
ogies: absorption at 260 nm and fluorescence excitation
(at 485 nm) and emission (detected at 538, 535 or 520
nm). Protocols varied in the number of repeat estimations
from four repeats (one participant) to three (six partici-
pants) and below.
Statistical methods
Statistical analysis of the data was carried out using the
SAS JMP package [11]. A mixed effect model was fitted to
the data, specifying the method of taking measurements
and the nominal concentrations as well as their interac-
tion as discrete fixed effects, while the laboratory as ran-
dom and nested within the methods effect. The properties
and the usefulness of mixed effect models have been com-
prehensively reviewed [12].
Results and discussion
It was considered advantageous that this study should
include academic as well as commercial participants since
harmonisation is necessary if genotyping bottlenecks are
to be minimised. Recruitment of participants posed little
problem. This was probably due to endorsement of the
study by P3G and de-identification of participants.
DNA was extracted, diluted and despatched as described.
Polypropylene plates containing DNA solutions at nomi-
nal concentrations known only to the coordinating centre
were despatched to 15 participants. Plates were not des-
patched to two potential participants because of adminis-
trative difficulties with carriers. Improved communication
among participants should eliminate this difficulty.
Participants were asked to use their standard operating
procedures to estimate DNA concentration and to return
data within 28 days. This was achieved in many cases.
Improved communications within participants' labs
should serve to expedite data return.
Data sets were returned by 13 participants. A total of 2514
observations were reported: 1118 measurements on DNA
solutions as provided and 1396 measurements on DNA
solutions diluted by participants.
Data were analysed to identify the impact of using differ-
ent methods in different laboratories for estimating DNA
concentrations. The variance of the difference between the
measured concentrations and the nominal concentration
Table 1: Summary of fit, Analysis
Summary of fit
RSquare 0.591098
RSquare Adj 0.583644
Root Mean Square Error 0.26306
Mean of Response 1.36344
Observations (or Sum Wgts) 1118
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 20 109.73814 5.48691 79.2899
Error 1097 75.91307 0.06920 Prob > F
C. Total 1117 185.65122 <.0001
Lack of Fit
Source DF Sum of Squares Mean Square F Ratio
Lack of Fit 91 49.191066 0.540561 20.3504
Pure Error 1006 26.722007 0.026563 Prob > F
Total Error 1097 75.913072 <.0001
Max RSq
0.8561BMC Research Notes 2009, 2:208 http://www.biomedcentral.com/1756-0500/2/208
Page 4 of 8
(page number not for citation purposes)
was seen to increase with the nominal concentration for
all methods and for all laboratories. However, the vari-
ance of the ratio
was homogeneous. The results of the study were therefore
summarised with respect to R. When R = 1, the measure-
ments confirm precisely the nominal concentrations.
There is no expectation that R shall be unity since the
measurement of the original DNA stock concentration is
not absolute.
Data were analysed for all concentration measurements. A
mixed effect model was fitted to the data, specifying the
method of taking measurements and the nominal concen-
trations as well as their interaction as discrete fixed effects,
while the laboratory were taken as random and nested
within the methods effect. Considering the data as a
whole, and based on 1118 observations (compared with
1280 expected observations), the data indicate from the
summary of fit, from the analysis of variance and from
analysis of lack of fit (Table 1) that there is considerable
overall variability. This makes it difficult to draw other
conclusions firmly.
The data were analysed to examine the effects of partici-
pant, technology and instrument. Figures 1, 2, 3, 4 show
R =
Measured concentration
Nominal concentration
Variability charts by technology and participant Figure 1
Variability charts by technology and participant. Variability charts for R and the standard deviation for each participant 
using (A) absorption spectroscopy and (B) fluorescence emission spectroscopy.
A 
 
B 
 
R
0.5
1.0
1.5
2.0
2.5
3.0
1 4 6 7 8 9 10 11
Participant
S
t
d
 
D
e
v
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
1 4 6 7 8 9 10 11
Participant
R
0.5
1.0
1.5
2.0
2.5
1 2 3 5 12 13
Participant
S
t
d
 
D
e
v
0.0
0.1
0.2
0.3
0.4
0.5
1 2 3 5 12 13
ParticipantBMC Research Notes 2009, 2:208 http://www.biomedcentral.com/1756-0500/2/208
Page 5 of 8
(page number not for citation purposes)
the variability in R by its mean and its standard deviation
for each technology by participants (Figure 1), by instru-
ment (Figure 2), by nominal concentration (Figure 3) and
by participant and nominal concentration (Figure 4).
There was strong evidence that there is a statistically signif-
icant difference between technologies: i.e. fluorescence
emission produces results showing less variability than
produced by absorption spectroscopy. Note that this does
not necessarily mean that the former technology is intrin-
sically less variable than the latter and that therefore the
latter technology should be abandoned. It means only
that the deployment of the latter technology can generate
greater variability than the former. Detailed methods
analysis will establish whether it is more practical or effi-
cient or quicker to reduce variability associated with one
or the other technology.
There was also strong evidence that there is a statistically
significant difference between participants (Figures 1 and
4). However, as all except one participant have used a sin-
gle method, this difference may be due to the instrument
or technology, rather than the participant. Participants 1,
2, 3 and 5 seem to have obtained results with lower varia-
bility than the others, although it should be borne in
mind that the overall variability subverts this conclusion.
Differences between participants may have causes that
overlap with the causes of variability from an individual
participant. For example, if different operators perform
differently within a lab, those differences may be the same
for operators in separate labs. Participants that strictly
adhere to quality standards such as ISO9001-2000 should
show less within-lab variability. However, even if two par-
ticipants implement strictly a standard such as ISO9001-
Variability charts by technology and instrument Figure 2
Variability charts by technology and instrument. Variability charts for R and the standard deviation for each instrument 
using (A) absorption spectroscopy and (B) fluorescence emission spectroscopy. The instrument number identifies one of the 
instruments listed under Materials and Methods.
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2000, there may still be substantial between-lab variabil-
ity owing to lack of identity or lack of precision within one
or both of their standard operating procedures or owing
to environmental variability.
For each of the nominal concentrations of DNA, variabil-
ity remained high regardless of technology and partici-
pant (Figures 3 and 4). This runs counter to the
conventional wisdom that very low or very high DNA con-
centrations are more difficult to measure accurately. It
does not address the question of whether there are the
same or different major sources of variability as DNA con-
centration changes. In this pilot study, no attempt was
made to assess variability associated with different DNA
molecular weights.
Conclusion
This is the first reported observational study on DNA con-
centration estimation among both academic and com-
mercial participants. We have demonstrated the feasibility
of an international DNA concentration estimation har-
monisation project involving both academic and com-
mercial participants. We provide evidence for significant
variation in DNA concentration estimation within and
between laboratories. This therefore has confirmed anec-
dotal evidence for such variation.
This evidence justifies undertaking systematic investiga-
tions into the sources of error and the identification, test-
ing, verification and implementation of remedial action
that will reduce DNA concentration estimation variabil-
ity. Such investigations will provide the evidence base for
Variability charts by nominal technology and concentration Figure 3
Variability charts by nominal technology and concentration. Variability charts for R and the standard deviation at each 
nominal concentration of DNA provided to participants using (A) absorption spectroscopy and (B) fluorescence emission 
spectroscopy.
A 
 
 
B 
 
R
0.5
1.0
1.5
2.0
2.5
3.0
10 20 40 50 75 100 150 300
Nominal conc
S
t
d
 
D
e
v
0.0
0.1
0.2
0.3
0.4
0.5
10 20 40 50 75 100 150 300
Nominal conc
R
0.5
1.0
1.5
2.0
2.5
10 20 40 50 75 100 150 300
Nominal conc
S
t
d
 
D
e
v
0.0
0.1
0.2
0.3
0.4
0.5
10 20 40 50 75 100 150 300
Nominal concBMC Research Notes 2009, 2:208 http://www.biomedcentral.com/1756-0500/2/208
Page 7 of 8
(page number not for citation purposes)
Variability charts by technology, participant and nominal concentration Figure 4
Variability charts by technology, participant and nominal concentration. Variability charts for R and the standard 
deviation for each participant at each nominal concentration of DNA provided using (A) absorption spectroscopy and (B) flu-
orescence emission spectroscopy. The instrument number identifies one of the instruments listed under Materials and Meth-
ods.
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protocol modification. Improvements in the consistency
of measurement of DNA are essential for efficient geno-
typing; for implementing ambitious experimental designs
in genetic epidemiology; and for compliance with quality
assurance recommendations (e.g. from the Organisation
for Economic Cooperation and Development [13]) and
requirements (e.g. for continued ISO9001-2000 accredi-
tation).
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